Earnings Releases·Nov 5, 2026, 4:01 PM ET

Omada Health — Q3 2026 Earnings Summary

Revenue reached $91 million in Q3 2026, a 34% year-over-year increase from $68 million, while the company reported a net income turnaround to $7 million from a $3 million loss in the prior year period.
Full-year 2026 guidance was raised to $344–$346 million in revenue (up from $334–$340 million) and $32–$34 million in Adjusted EBITDA (up from $21–$27 million), reflecting approximately 33% projected revenue growth.
Total members grew 36% year-over-year to 1.1 million with average tenure increasing 10% to roughly 2 years and 4 months, driven by enrollment in diabetes and hypertension programs.
Gross margins improved significantly with GAAP margins rising to 76% and Non-GAAP margins to 78%, while free cash flow for the nine months ended September 30, 2026, turned positive at $2.5 million compared to a $7.6 million loss previously.